A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.
Morten Mau-Soerensen
Research Funding - Karyopharm Therapeutics
Albiruni R. A. Razak
Research Funding - Karyopharm Therapeutics
Anthony Frank Shields
No relevant relationships to disclose
Nashat Y. Gabrail
No relevant relationships to disclose
John F. Gerecitano
No relevant relationships to disclose
Sharon Shacham
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Ulrik Niels Lassen
No relevant relationships to disclose
Tami Rashal
Employment or Leadership Position - Karyopharm Therapeutics (B)
Stock Ownership - Karyopharm Therapeutics
Jennifer Cooksey
No relevant relationships to disclose
Yosef Landesman
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Gregory Pond
No relevant relationships to disclose
Amit M. Oza
No relevant relationships to disclose
Michael Kauffman
Employment or Leadership Position - Karyopharm Therapeutics (B)
Stock Ownership - Karyopharm Therapeutics (B)
Lillian L. Siu
Research Funding - Karyopharm Therapeutics
Philippe L. Bedard
No relevant relationships to disclose
Hemchandra Mahaseth
No relevant relationships to disclose
Mansoor Raza Mirza
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Amit Mahipal
Research Funding - Karyopharm Therapeutics